Humana (NYSE:HUM) Issues FY 2025 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 16.250-16.250 for the period, compared to the consensus EPS estimate of 16.910. The company issued revenue guidance of -.

Humana Trading Down 2.7 %

NYSE:HUM opened at $266.91 on Tuesday. The company has a 50-day moving average price of $274.21 and a 200-day moving average price of $297.52. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market cap of $32.14 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 2.11 and a beta of 0.56.

Analyst Ratings Changes

Several equities research analysts have recently commented on HUM shares. Wells Fargo & Company dropped their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Barclays lifted their price target on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 22nd. Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. TD Cowen lifted their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Morgan Stanley lifted their price target on shares of Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $297.68.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.